Large variation in anti-factor Xa levels with nadroparin as thromboprophylaxis in COVID-19 and non-COVID-19 critically ill patients

Table 2 Prophylactic nadroparin dosage and anti-FXa levels

Characteristic	Total n = 62	COVID-19 n = 30	Non-COVID-19 n = 32
LMWH dose
2850 IU OD	30 (48%)	-	30 (94%)
5700 IU OD	21 (34%)	19 (63%)	2 (6%)
5700 IU BID	11 (18%)	11 (37%)	-
Anti-FXa level (IU/ml)
Total	0.24 (0.11-0.33)	0.32 (0.24-0.56)	0.12 (0.00-0.25)
2850 IU OD	-	-	0.11 (0.00-0.24)
5700 IU OD	0.28 (0.23-0.44)	0.27 (0.23–0.48)	0.31 (0.30-0.31)^a
5700 IU BID	-	0.52 (0.34–0.88)	-
Category Anti-FXa level IU/ml)
0.20–0.50	31 (50%)	19 (63%)	12 (38%)
> 0.50	10 (16%)	10 (33%)	-
< 0.20	21 (34%)	1 (3%)	20 (63%)
< 0.10 (undetectable)	11 (18%)	-	11 (34%)

Data are medians with interquartile ranges in parentheses unless otherwise stated
Anti-FXa-levels = Anti-Factor Xa-levels, BID = twice daily, COVID-19 = Corona Virus Infectious Disease-2019, IU = International Unit, OD = once daily
Values above 0.50 IU/ml were in the range of 0.51–1.20 IU/ml of which 5 were above 0.60 IU/ml. Those 5 anti-FXa levels are considered in the therapeutic range of nadroparin treatment.
^atwo patients of which anti-FXa level was 0.30 IU/ml and 0.31 IU/ml

ISSN: 2050-6511